Safe Chronic Suppurative Otitis Media (Tubotympanic Disease)

Otoscopic view: central tympanic membrane perforation with mucoid discharge — classic Safe CSOM

Definition & Terminology

Epidemiology & Risk Factors

• Most prevalent in children < 2 years, low-income settings with limited healthcare access
• Global burden is significant — a 2025 systematic review estimated CSOM affects a substantial portion of children in lower-resource regions
• Risk factors:
  • Multiple/recurrent episodes of acute otitis media (AOM)
  • AOM in early infancy
  • Chronic secretory OM
  • Eustachian tube (ET) dysfunction
  • Tympanostomy tubes or TM perforation allowing external contamination
  • Genetic predisposition (Native Americans, Inuit, Native Australians, Māori)
  • Nasopharyngeal reflux

Pathogenesis

Eustachian Tube Dysfunction — Central Mechanism

1. Abnormal ET function → decreased middle ear (ME) aeration
2. Nitrogen-absorbing cells in mastoid reduce ME volume
3. Negative ME pressure develops
4. TM retraction — most susceptible area is pars flaccida (atticoantral); in tubotympanic disease, retraction confined to pars tensa
5. Perforation acts as a compensatory mechanism for aeration

Role of Biofilms

• Highly organized networks of sessile bacteria enclosed in oligopolysaccharide matrix
• Escape phagocytosis and humoral immunity due to impenetrable matrix
• Gain protection from pH/temperature changes
• Decreased metabolic rate and altered gene expression
• Produce efflux pumps against antibiotics → high resistance
• Frequently polymicrobial — harder to target
• May be adherent to respiratory epithelium, within mucus, or intracellular (reservoir for persistent infection)

Bacteriology

Clinical Features

Symptoms

• Chronic or recurrent otorrhea — typically mucoid/mucopurulent, odourless (distinguishes from unsafe type)
• Conductive hearing loss — usually low-frequency; mixed hearing loss can occur
• Aural fullness
• Rarely: otalgia (suggests complication)

Signs

• Central TM perforation (pars tensa) — the hallmark; margins do not reach the annulus
• ME mucosal inflammation
• Granulation tissue / aural polyps (may obscure landmarks)
• No cholesteatoma — if keratin debris or foul odour is present, re-classify as unsafe
• Complicated CSOM may show facial nerve paresis, vertigo (labyrinthine fistula), or signs of intracranial infection — though these are far more common in the unsafe type

Diagnosis

Key Principle

Assessment Tools

Treatment

Primary Goal

"Creation of a safe, dry ear"

• Dry = no otorrhea
• Safe = no keratin debris collection, reduced risk of suppurative complications

Step 1: Aural Toilet

Step 2: Medical Management

• Fluoroquinolones (e.g., ciprofloxacin/ofloxacin ear drops) — preferred due to P. aeruginosa coverage and safety profile; 4–6 week course following debridement
• Polymyxin B or neomycin (±steroid)
• Note: biofilms frequently resist topical medication; multicellular strategies overcome even high antibiotic concentrations

Step 3: Surgery

Tympanoplasty (Myringoplasty)

• Closure of TM perforation (pars tensa)
• Success rate: 60–90%
• Favourable predictor: patient able to insufflate air through the perforation (Valsalva manoeuvre)
• Timing in children: generally deferred until ~10 years — older children have better outcomes due to more mature ET function
  • Earlier surgery if troublesome otorrhea or significant hearing loss
  • Contralateral ear health is a more reliable predictor of success than age alone
• Graft materials: temporalis fascia, perichondrium, cartilage

Tympanomastoidectomy

• Suspected or confirmed cholesteatoma
• Otorrhea refractory to medical treatment
• TM perforation closure rates are not increased by concomitant mastoidectomy alone

• Remove all cholesteatoma
• Remove all granulation tissue
• Restore continuity between ME cleft and mastoid cavity

• Atticotomy (transcanal)
• Canal wall up (CWU) — preferred in children; lower morbidity, no cavity maintenance required
• Canal wall down (CWD) with or without obliteration
• Modified radical / Bondy procedure

Eustachian Tube Interventions

• Balloon tuboplasty, laser tuboplasty, ET implants (stenting) — no ET treatment has demonstrated long-term efficacy

Complications

• Conductive hearing loss (most common)
• Sensorineural hearing loss (toxins tracking to round window)
• Tympanosclerosis
• Facial nerve palsy (rare)
• Labyrinthitis

• Meningitis
• Brain abscess
• Sigmoid sinus thrombosis
• Subdural/extradural abscess

Special Situation: CSOM and Cochlear Implantation

• Implant if the ear is dry at time of surgery
• Multiple protocols exist: single-stage vs two-stage (mastoid obliteration first, then CI 2–6 months later)
• All patients receive perioperative antimicrobial prophylaxis (Cummings Otolaryngology Head and Neck Surgery)

Summary Comparison: Safe vs Unsafe CSOM

SAFE (Tubotympanic)            UNSAFE (Atticoantral)
───────────────────────────    ──────────────────────────
Central perforation            Marginal/attic perforation
Pars tensa                     Pars flaccida
Mucoid, odourless discharge    Scanty, foul-smelling
No cholesteatoma               Cholesteatoma present
Mucosal disease                Squamosal disease
Medical ± tympanoplasty        Surgery mandatory
Fewer complications            Higher complication risk

• K J Lee's Essential Otolaryngology, 11th ed.
• Cummings Otolaryngology Head and Neck Surgery, 7th ed.
• Harriet Lane Handbook, 23rd ed.
• Onifade et al. (2025) — Epidemiology of CSOM: global prevalence [PMID: 40178730]
• Chong et al. (2025) — Cochrane: Systemic antibiotics for CSOM [PMID: 40484405]